FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of colon cancer. Presented is a method of treating colon cancer involving administering a pharmaceutically acceptable amount of a PDE1 inhibitor to a subject in need thereof, wherein the PDE1 inhibitor is
or 
in free form or in the form of a pharmaceutically acceptable salt. Also disclosed is an embodiment of said method, comprising additionally administering a PD-1 inhibitor, and a method of inhibiting proliferation, migration and/or invasion of cancer or tumour cells in the colon, comprising administering a pharmaceutically acceptable amount of said PDE1 inhibitor to a subject in need thereof suffering from colon cancer.
EFFECT: invention provides effective treatment of colon cancer.
11 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER DISEASES AND TUMORS USING PDE1 INHIBITORS | 2019 |
|
RU2811918C2 |
| ANTITUMOUR AGENT | 2006 |
|
RU2391982C2 |
| COMBINED DRUG FOR TREATMENT OF TUMOR DISEASES | 2002 |
|
RU2291710C2 |
| ANTICANCER COMPOSITION CONTAINING A RECOMBINANT ADENOVIRUS EXPRESSING A DESTRUCTIVE FACTOR FOR AN EXTRACELLULAR MATRIX | 2017 |
|
RU2742726C2 |
| METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION | 2014 |
|
RU2666921C2 |
| USE OF THE PLINABULIN IN COMBINATION WITH THE IMMUNE RESPONSE CONTROL POINT INHIBITORS | 2016 |
|
RU2723021C2 |
| COMPOSITIONS CONTAINING TUCARESOL OR ANALOGUES THEREOF | 2017 |
|
RU2753543C1 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
| IMMUNO-ONCOTHERAPEUTIC COMPOSITION USING ADJUVANT COMPRISING LIPOPEPTIDES AND POLY(I:C) | 2022 |
|
RU2837689C2 |
| PREPARATION POTENTIATING RADIATION THERAPY | 2007 |
|
RU2435587C2 |
